Prime Medicine, Inc.

MONTREAL, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces that further to its news releases dated July 30, August 14 and August 27, 2026, the Company voluntarily applied for and the Company's principal regulator, the British Columbia Securities Commission (the “BCSC”) granted a management cease trade order (the “MCTO”) dated July 30, 2026, under National Policy 12-203 Management Cease Trade Orders (“NP 12-203”) and provided the Company with an extension to file its annual financial statements for the year ended March 31, 2026, including the related management's discussion and analysis, and Chief Executive Officer and Chief Financial certifications on or before July 29, 2026 (collectively the “Annual Financial Filings”). The deadline has been extended to on or before September 28, 2026.

CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that company management will participate in three upcoming conferences: Wells Fargo 21st Annual Healthcare Conference: Company management will host 1x1 meetings on Thursday, September 10, 2026, in Boston, MA.

BlackRock Inc. acquired a new stake in shares of Prime Medicine, Inc. (NASDAQ: PRME) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 9,602,041 shares of the company's stock, valued at approximately $35,432,000. BlackRock Inc. owned about 5.32% of Prime Medicine

Prime Medicine trades at a $548M valuation, significantly undervaluing its broad, potentially best-in-class gene-editing pipeline. PRME's therapies target five indications across liver, lung, and immunology/oncology, with leading preclinical efficacy and multi-billion-dollar addressable markets. Recent IND/CTA clearances, RMAT designation, and patent wins highlight PRME's clinical and strategic momentum despite a 54% stock decline from 52-week highs.